COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,082 Articles (22,658 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 633: Articles 6321-6330  | Next

Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination
Buckner, C., Kardava, L., El Merhebi, O., Narpala, S., Serebryannyy, L., Lin, B., Wang, W., Zhang, X., Lopes de Assis, F., Kelly, S., Teng, I.-T., McCormack, G., Praiss, L., Seamon, C., Rai, M. A., Kalish, H., Kwong, P., Proschan, M., McDermott, A., Fauci, A., Chun, T.-W., Moir, S.
10.1101/2022.08.30.22279344 — Posted: 2022-08-31
Evidence for coordinated evolution at amino acid sites of SARS-CoV-2 spike
Neverov, A. D., Fedonin, G., Popova, A., Bykova, D., Bazykin, G.
10.1101/2022.08.30.505885 — Posted: 2022-08-30
Characterising Long Covid: a living systematic review update with controlled studies
Michelen, M., Sigfrid, L., Kartsonaki, C., Shemilt, I., Hastie, C., O'Hara, M. E., Suett, J. C., Stelson, E. A., Bugaeva, P., Dahmash, D., Rigby, I., Munblit, D., Harriss, E., Burls, A., Cheng, V., Scott, J. T., Carson, G., Olliaro, P. L., Stavropoulou, C.
10.1101/2022.08.29.22279338 — Posted: 2022-08-30
SOCIAL INEQUITIES IN A PSYCHOLOGICAL DOMAIN OF FOOD INSECURITY AMONG MOTHERS FROM SOUTHERN BRAZIL DURING THE COVID-19 PANDEMIC
Martins-Silva, T., Carpena, M. X., Blumenberg, C., Martins, R. C., Olazo, K. M., Marmitt, L. P., Meucci, R., Cesar, J. A., Trude, A. C. B., Loret de Mola, C.
10.1101/2022.08.26.22279279 — Posted: 2022-08-30
GHSI COVID-19 puzzle: did highly developed countries indeed fare worse?
Markovic, S., Salom, I., Rodic, A., Djordjevic, M.
10.1101/2022.08.28.22279258 — Posted: 2022-08-30
BindingSiteAugmentedDTA: Enabling A Next-Generation Pipeline for Interpretable Prediction Models in Drug-Repurposing
Yousefi, N., Yazdani-Jahromi, M., Tayebi, A., Kolanthai, E., J. Neal, C., Banerjee, T., Gosai, A., Balasubramanian, G., Seal, S., Ozmen Garibay, O.
10.1101/2022.08.30.505897 — Posted: 2022-08-30
Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2
Farrell, A. G., Dadonaite, B., Greaney, A. J., Eguia, R., Loes, A. N., Francko, N. M., Logue, J., Carreno, J. M., Abbad, A., Chu, H. Y., Matreyek, K. A., Bloom, J. D.
10.1101/2022.08.29.505713 — Posted: 2022-08-30
Entropic overcompensation of the N501Y mutation on SARS-CoV-2 S binding to ACE2
Gupta Vergara, N., Gatchel, M., Abrams, C. F.
10.1101/2022.08.30.505841 — Posted: 2022-08-30
Polygenic Risk Scores for Asthma and Allergic Disease Predict COVID-19 Severity in 9/11 Responders
Waszczuk, M., Morozova, O., Lhuillier, E., Docherty, A., Shabalin, A., Yang, X., Carr, M., Clouston, S., Kotov, R., Luft, B.
10.1101/2022.08.30.22279383 — Posted: 2022-08-30
Organizational impact of an ID NOW COVID-19 point-of-care testing for SARS-CoV2 detection in a maternity ward
Nguyen Van, J.-C., Pilmis, B., Khaterchi, A., Billuart, O., Pean de Ponfilly, G., Le Monnier, A., Azria, E., Mizrahi, A.
10.1101/2022.08.29.22279161 — Posted: 2022-08-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).